1,472 results on '"Zeiser, Robert"'
Search Results
2. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
3. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
4. How risky is a second allogeneic stem cell transplantation?
5. 15-year remission in refractory FLT3-mutated AML attained by sorafenib
6. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
7. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
8. Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease
9. Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment
10. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease
11. IL-23 stabilizes an effector Treg cell program in the tumor microenvironment
12. Acute Graft-Versus-Host Disease
13. Multiomic spatial landscape of innate immune cells at human central nervous system borders
14. A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study
15. Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease
16. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
17. A new silicon phthalocyanine dye induces pyroptosis in prostate cancer cells during photoimmunotherapy
18. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
19. The role of the MDM2/p53 axis in antitumor immune responses
20. Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure
21. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
22. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
23. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
24. Granulocyte-Macrophage Colony-Stimulating Factor in Allogenic Hematopoietic Stem Cell Transplantation: From Graft-versus-Host Disease to the Graft-versus-Tumor Effect
25. CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice
26. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
27. A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease
28. Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function
29. GPRC5C drives branched-chain amino acid metabolism in leukemogenesis
30. Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape
31. Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia
32. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms
33. Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
34. Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
35. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
36. Contributors
37. Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis
38. Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation
39. Anti–PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation
40. Retinoic acid signaling acts as a rheostat to balance Treg function
41. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality
42. Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality
43. Fever supports CD8⁺ effector T cell responses by promoting mitochondrial translation
44. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation
45. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force
46. Three US Food and Drug Administration–approved therapies for chronic GVHD
47. Hämatologische und onkologische Notfälle.
48. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial
49. FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
50. Editorial: Transcriptional and epigenetic regulation in normal and aberrant hematopoiesis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.